Burkitt and Burkitt-Like Lymphomas: a Systematic Review

AbstractPurpose of ReviewBurkitt ’s lymphoma and its leukemic form (Burkitt cell acute lymphoblastic leukemia) are a highly aggressive disease. We review the classification, clinical presentation, histology, cytogenetics, and the treatment of the disease.Recent FindingsBurkitt ’s lymphoma might be associated with tumor lysis syndrome which is a potentially fatal complication that occurs spontaneously or upon initiation of chemotherapy. Major improvements were made in the treatment of pediatric and adults population using short-course dose-intensive chemotherapy regimens , usually 1 week after a prephase induction. Addition of Rituximab to chemotherapy has become a standard of care. Relapsed/refractory disease has a very poor prognosis and the benefit from autologous/allogeneic hematopoietic stem cell transplant remains uncertain.SummaryRituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt ’s lymphoma even in the immunodeficiency-related form.

Source: Current Oncology Reports - March 5, 2020 Category: Cancer & Oncology Source Type: research